S Peters, S Loi, F André, S Chandarlapaty, E Felip, S P Finn, P A Jänne, K M Kerr, E Munzone, A Passaro, M Pérol, E F Smit, C Swanton, G Viale, R A Stahel
Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in clinical development. In lung cancer, trastuzumab deruxtecan (T-DXd) is approved in human epidermal growth factor receptor 2 (HER2)-mutated, unresectable or metastatic non-small cell lung cancer, with ADCs targeting HER3 (patritumab deruxtecan), trophoblast cell-surface antigen 2 (datopotamab deruxtecan and sacituzumab govitecan [SG]) and mesenchymal-epithelial transition factor (telisotuzumab vedotin) in late-stage clinical development...
April 20, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology